Although LSM1 was identified as a key differentiator between prognostic groups (P = 4.5E-03, Fig. 2), there was no significant difference in its expression levels between MCL and reactive lymph nodes (p < 0.05, Supplementary Fig. 1A), contrary to LSM8. This finding suggests that although LSM1 may play a role in the biological differences between prognostic groups, it may not be a specific biomarker for distinguishing between MCL and reactive lymph nodes. This evidence concerns the gene LSM1 and mantle cell lymphoma.